These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30181817)

  • 1. Correction: CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia.
    Guerra B; Martín-Rodríguez P; Díaz-Chico JC; McNaughton-Smith G; Jiménez-Alonso S; Hueso-Falcón I; Montero JC; Blanco R; León J; Rodríguez-González G; Estévez-Braun A; Pandiella A; Díaz-Chico BN; Fernández-Pérez L
    Oncotarget; 2018 Aug; 9(63):32272. PubMed ID: 30181817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia.
    Guerra B; Martín-Rodríguez P; Díaz-Chico JC; McNaughton-Smith G; Jiménez-Alonso S; Hueso-Falcón I; Montero JC; Blanco R; León J; Rodríguez-González G; Estévez-Braun A; Pandiella A; Díaz-Chico BN; Fernández-Pérez L
    Oncotarget; 2017 May; 8(18):29679-29698. PubMed ID: 27557509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An analysis of strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia with imatinib-resistant mutations.
    Paquin D; Sacco D; Shamshoian J
    Math Biosci; 2015 Apr; 262():117-24. PubMed ID: 25659886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
    Taylor MJ; Scuffham PA
    Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):117-21. PubMed ID: 19402798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.
    Ju DS; Kim MJ; Bae JH; Song HS; Chung BS; Lee MK; Kang CD; Lee HS; Kim DW; Kim SH
    Cancer Lett; 2007 Jul; 252(1):75-85. PubMed ID: 17223257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities.
    Ciftci HI; Ozturk SE; Ali TFS; Radwan MO; Tateishi H; Koga R; Ocak Z; Can M; Otsuka M; Fujita M
    Biol Pharm Bull; 2018 Apr; 41(4):570-574. PubMed ID: 29386476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of human chronic myelogenous leukemia K562 cell growth following combination treatment with resveratrol and imatinib mesylate.
    Wang XJ; Li YH
    Genet Mol Res; 2015 Jun; 14(2):6413-8. PubMed ID: 26125846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction: A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy.
    Hsu TI; Chen YJ; Hung CY; Wang YC; Lin SJ; Su WC; Lai MD; Kim SY; Wang Q; Qian K; Goto M; Zhao Y; Kashiwada Y; Lee KH; Chang WC; Hung JJ
    Oncotarget; 2019 Nov; 10(60):6536-6537. PubMed ID: 31741716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suboptimal responses to imatinib in chronic myelogenous leukemia: what are they and how do they affect treatment?
    Allen-Bard S
    Clin J Oncol Nurs; 2009 Oct; 13(5):537-42. PubMed ID: 19793710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins.
    Li L; Xu N; Zhang JF; Xu LL; Zhou X; Huang BT; Li YL; Liu XL
    Int J Med Sci; 2016; 13(5):365-73. PubMed ID: 27226777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate.
    Illmer T; Schaich M; Platzbecker U; Freiberg-Richter J; Oelschlägel U; von Bonin M; Pursche S; Bergemann T; Ehninger G; Schleyer E
    Leukemia; 2004 Mar; 18(3):401-8. PubMed ID: 14724652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of A Novel Emodin Derivative on Chronic Myelogenous Leukemia K562 Cells and Imatinib-resistant K562/G01 Cells].
    Li BJ; Liu TB; Wang WF; Lin MH; Hu JD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):1-7. PubMed ID: 26913384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia.
    Singh T; Casson C
    Am J Ther; 2007; 14(5):484-7. PubMed ID: 17890939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.
    Hochhaus A; La Rosée P
    Leukemia; 2004 Aug; 18(8):1321-31. PubMed ID: 15215876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of galectin-1 as a novel mediator for chemoresistance in chronic myeloid leukemia cells.
    Luo W; Song L; Chen XL; Zeng XF; Wu JZ; Zhu CR; Huang T; Tan XP; Lin XM; Yang Q; Wang JZ; Li XK; Wu XP
    Oncotarget; 2016 May; 7(18):26709-23. PubMed ID: 27050374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib alone and in combination for chronic myeloid leukemia.
    Druker BJ
    Semin Hematol; 2003 Jan; 40(1):50-8. PubMed ID: 12563611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells.
    D'Asaro M; La Mendola C; Di Liberto D; Orlando V; Todaro M; Spina M; Guggino G; Meraviglia S; Caccamo N; Messina A; Salerno A; Di Raimondo F; Vigneri P; Stassi G; Fourniè JJ; Dieli F
    J Immunol; 2010 Mar; 184(6):3260-8. PubMed ID: 20154204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia.
    Yamamoto M; Kakihana K; Kurosu T; Murakami N; Miura O
    Cancer Genet Cytogenet; 2005 Mar; 157(2):104-8. PubMed ID: 15721630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel compound against oncogenic Aurora kinase A overcomes imatinib resistance in chronic myeloid leukemia cells.
    Long ZJ; Wang LX; Zheng FM; Chen JJ; Luo Y; Tu XX; Lin DJ; Lu G; Liu Q
    Int J Oncol; 2015; 46(6):2488-96. PubMed ID: 25872528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.